Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)

NCT00668616 is registered in ClinicalTrials.gov with North Eastern German Society of Gynaecological Oncology as lead sponsor.

NCT NCT00668616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00668616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2000
Completion date
July 31, 2009
Enrollment
1,034 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer